A compound represented by: a. the formula below: or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each occurrence, A is an optionally substituted_aryl; R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-pyrrolindinyl), optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; provided that the compound is not 1-[1-(4-fluorophenyl)-2,5-dimethlypyrrol-3-yl]-2-pyrrolidin-1-ylethanone; or b. the formula below: or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each occurrence, A is selected from the group consisting of and R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-piperidinyl) or-CH 2 (N-pyrrolindinyl), each optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl. a. the formula below: or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each occurrence, A is an optionally substituted_aryl; R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-pyrrolindinyl), optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; provided that the compound is not 1-[1-(4-fluorophenyl)-2,5-dimethlypyrrol-3-yl]-2-pyrrolidin-1-ylethanone; or A is an optionally substituted_aryl; R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-pyrrolindinyl), optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; provided that the compound is not 1-[1-(4-fluorophenyl)-2,5-dimethlypyrrol-3-yl]-2-pyrrolidin-1-ylethanone; or b. the formula below: or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each occurrence, A is selected from the group consisting of and R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-piperidinyl) or-CH 2 (N-pyrrolindinyl), each optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl. A is selected from the group consisting of and R 1 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; R 2 is hydrogen, alkyl, haloalkyl, C 1 -C 6 alkoxy, or halo; Z is =C(R 8)-; X is Y is -CH 2 (N-piperidinyl) or-CH 2 (N-pyrrolindinyl), each optionally substituted; and R 8 is hydrogen, alkyl, substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl.